Terms: = Ovarian cancer AND PTPRC, LCA, 5788, ENSG00000081237, T200, GP180, B220, LY5, CD45 AND Clinical Outcome
3 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Fusion Cell Markers in Circulating Tumor Cells from Patients with High-Grade ovarian Serous Carcinoma.
Ruano APC; Gadelha Guimarães AP; Braun AC; Flores BCTCP; Tariki MS; Abdallah EA; Torres JA; Nunes DN; Tirapelli B; de Lima VCC; Fanelli MF; Colombo PE; da Costa AABA; Alix-Panabières C; Chinen LTD
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499015
[TBL] [Abstract] [Full Text] [Related]
3. AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.
Svoboda M; Meshcheryakova A; Heinze G; Jaritz M; Pils D; Castillo-Tong DC; Hager G; Thalhammer T; Jensen-Jarolim E; Birner P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Zimmermann P; Zeillinger R; Mechtcheriakova D
BMC Genomics; 2016 Aug; 17(1):643. PubMed ID: 27527602
[TBL] [Abstract] [Full Text] [Related]
